Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea

Lee, Seung Hun; Gong, Hyun Sik; Kim, Tae-Hee; Park, Si Young; Shin, Jung Hoon; Cho, Sun Wook; Byun, Dong Won

doi:10.11005/jbm.2015.22.4.167

Cited by 22 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[56] During drug holiday, a significant decrease in BMD or a significant increase in BTMs suggests that the residual effect of BP therapy may be diminishing and that it may be time to resume active therapy. [525758] Roberts and colleagues [51] recommended that if BTMs rise over 30% after drug holiday, treatment should be resumed.…”

Section: Clinical Utility Of Btmsmentioning

confidence: 99%

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

et al. 2019

Self Cite

View full text Add to dashboard Cite

Current evidences continue to support the clinical application of bone turnover markers (BTMs) in the management of postmenopausal osteoporosis. The limitations of bone mineral density measured by dual energy X-ray absorptiomet especially emphasize the beneficial roles of BTMs, such as serum C-terminal telopeptide of type I collagen and serum procollagen type I N-propeptide, as monitoring tools to assess the responses to treatment. Therefore, the proper application and assessment of BTM in clinical practice is very important. However, their use in Korea is still insufficient. Therefore, the BTM committee has set up by the Korean Society for Bone and Mineral Research have been constituted and provided a position statement which will suggest on the clinical application of BTM for the management of postmenopausal osteoporosis in Korea.

show abstract

Section: Clinical Utility Of Btmsmentioning

confidence: 99%

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…A drug holiday is believed to be one of the core components of MRONJ treatment, despite complications like osteoporotic fractures in the vertebrae, femur and pelvis. There have been some reports showing that a drug holiday can be acceptable without a significant rise of the complication rate [ 44 , 45 ]. However, the increased risk of osteoporotic fractures which may be fatal should not be ignored, because the safety issue of the drug holiday should be further investigated.…”

Section: Resultsmentioning

confidence: 99%

Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ)

Kwon

Kim

2016

Dentistry Journal

View full text Add to dashboard Cite

While the optimal treatment concept of medication-related osteonecrosis of the jaws (MRONJ) is still in debate, several adjunct therapies have been introduced. Among these adjunctive measures, recombinant human parathyroid hormone (rhPTH, teriparatide) seems to be the most promising treatment modality. Several studies have presented the beneficial effect of short-term teriparatide; they have shown an improved level of bone markers and radiographic evidence of bone healing. Although clinical validation by a controlled trial with prospective design would be essential, short-term teripratide therapy would be a good treatment option for MRONJ patients with impaired bone remodeling.

show abstract

“… 33 34 35 36 37 38 In our study, the cumulative probability of AFF abruptly increased at 4 years of bisphosphonate use, which support that expert opinions from western countries. 33 34 35 36 37 38 39 40 …”

Section: Discussionmentioning

confidence: 99%

Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea

et al. 2018

View full text Add to dashboard Cite

BackgroundAtypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of bisphosphonate.MethodsWe conducted a hospital-based, retrospective cohort study in patients aged ≥ 45 years, who took bisphosphonate. The occurrence of AFF was estimated by using incidence rate, and the age-adjusted incidence rate to U.S. 2010 Census data. The association between occurrence of AFF and the duration of bisphosphonate use was examined. The cumulative probability of AFF was plotted per each duration of bisphosphonate use.ResultsAmong 10,338 individuals who took bisphosphonate, 13 patients with AFF following use of bisphosphonate were identified. The incidence rate was 85.9/100,000 person-years (95% confidence interval [CI], 50.2–146.9), and age-adjusted incidence rate was 72.7/100,000 person-years (95% CI, 29.1–175.8). In Poisson regression analysis, higher body mass index (BMI) was associated with an increased risk of AFF (relative risk, 1.2; 95% CI, 1.004–1.359). The cumulative probability of AFF increased abruptly when the duration of bisphosphonate use was 4 years or more.ConclusionAmong Korean patients, the incidence rate of AFF was on a par with those of western countries, and this can provide basic information to conduct further studies by evaluating risk and benefit of continuing bisphosphonate.

show abstract

Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea

Cited by 22 publications

References 24 publications

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ)

Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea

Contact Info

Product

Resources

About